Comparison of Rosuvastatin versus Atorvastatin for Preventing Postoperative Atrial Fibrillation
DOI:
https://doi.org/10.1532/HSF98.20121061Abstract
Background: Postoperative atrial fibrillation (AF) following cardiac surgery is associated with an increased risk of stroke, prolonged hospitalization, and increased costs. Statin therapy is associated with a lower incidence of postoperative AF. We aimed to compare the preventive effects of rosuvastatin and atorvastatin on postoperative AF.
Methods: This study included 168 patients undergoing elective cardiac surgery with cardiopulmonary bypass. Patients were divided into 2 groups according to treatment of statin. Group 1 (n = 96) was patients receiving atorvastatin, and group 2 (n = 72) was patients receiving rosuvastatin. Postoperative electrocardiographs (ECGs) and telemetry strips were examined for AF within postoperative period during hospitalization.
Results: The incidences of postoperative AF were 17.9% (n = 17) in group 1 and 22.2% (n = 16) in group 2 (P = .48). Left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were not different between groups. Incidence of diabetes, hypertension, hyperlipidemia, smoking, myocardial infarction in past medical history, family history of atherosclerosis, male sex, drug use, and perioperative features were similar between groups.
Conclusions: The present study revealed that preoperative rosuvastatin or atorvastatin treatment did not have a different effect in preventing postoperative AF.
References
Almassi GH, Schowalter T, Nicolosi AC, et al. 1997. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 226:501-11.nAranki SF, Shaw DP, Adams DH, et al. 1996. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 94:390-7.nAviles RJ, Martin DO, Apperson-Hansen C, et al. 2003. Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006-10.nBanach M, Rysz J, Drozdz JA, et al. 2006. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J 70:438-41.nBoos CJ, Anderson RA, Lip GY. 2006. Is atrial fibrillation an inflammatory disorder? Eur Heart J 27:136-49.nCreswell LL, Schuessler RB, Rosenbloom M, Cox JL. 1993. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 56:539-49.nDotani MI, Elnicki DM, Jain AC, Gibson CM. 2000. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 86:1128-30.nFontes ML, Mathew JP, Rinder HM, et al. 2005. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 101:17-23.nEchahidi N, Mohty D, Pibarot P, et al. 2007. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 116(11 suppl):I-213-9.nFrost L, Mølgaard H, Christiansen EH, Hjortholm K, Paulsen PK, Thomsen PE. 1992. Atrial fibrillation and flutter after coronary artery bypass surgery: epidemiology, risk factors and preventive trials. Int J Cardiol 36:253-61.nGaudino M, Andreotti F, Zamparelli R, et al. 2003. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108 Suppl 1:II195-9.nHong YJ, Jeong MH, Hachinohe D, et al. 2011. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 75:398-406.nLertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. 2008. Preoperative statins for the prevention of atrial fibrillation aftercardiothoracic surgery. J Thorac Cardiovasc Surg 135:405-11.nLo B, Fijnheer R, Nierich AP, Bruins P, Kalkman CJ. 2005. C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg 79:1530-5.nMarín F, Pascual DA, Roldán V, et al. 2006. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97:55-60.nMartínez-González J, Raposo B, Rodríguez C, Badimon L. 2001. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 21:804-9.nMathew JP, Fontes ML, Tudor IC, et al. 2004. A multicenter risk index for atrial fibrillation after cardiac surgery. J Am Med Assoc 291:1720-9.nPatti G, Chello M, Candura D, et al. 2006. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114:1455-61.nPlenge JK, Hernandez TL, Weil KM, et al. 2002. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-52.nPound EM, Kang JX, Leaf A. 2001. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 42:346-51.nPsychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. 2005. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95:764-7.nResch U, Tatzber F, Budinsky A, Sinzinger H. 2006. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61:262-74.nSavelieva I, Kourliouros A, Camm J. 2010. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 381:383.nSong YB, On YK, Kim JH, et al. 2008. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 156:373.e9-16.nSuzumura K, Yasuhara M, Tanaka K, Suzuki T. 1999. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 57:697-703.nYoung-Xu Y, Jabbour S, Goldberg R, et al. 2003. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92:1379-83.n
